Skip to main content

Advertisement

SpringerLink
Log in

Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC). A total of 84 NSCLC patients were equally randomized into intervention group and control group. Both groups were intravenously administered with ondansetron 8 mg 30 min before chemotherapy. In the intervention group, olanzapin 10 mg was orally administered for 8 days, beginning from the first morning of chemotherapy. The antiemetic effectiveness was evaluated in the first chemotherapy cycle. The incidence of acute vomiting was 33.33 % (14/42) and 54.76 % (23/42) in the intervention group and control group (p < 0.05) whereas that of delayed vomiting was 16.57 % (7/42) and 47.62 % (20/42) (p < 0.05). Compared with ondansetron alone, the combination of olanzapine with ondansetron has better effectiveness in preventing CINV in NSCLC patients, particularly for the delayed type.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Robert, J., Ginsberg, H. J., & Lung, C. (2010). American Cancer Society Clinical Oncology Series (pp. 1–7). Beijing: China Medical Science and Technology Press.

    Google Scholar 

  2. Wiser, W., & Berger, A. (2005). Practical management of chemotherapy-induced nausea and vomiting. Oncology, 05, 637–645.

    Google Scholar 

  3. Shi, Y. K. (2008). Diagnosis and treatment of lung cancer (pp. 240–271). Beijing: People’s Health Publishing House.

    Google Scholar 

  4. Lin, C. (2011). Management of the toxicities of anti-cancer drugs. Programme for Japanese Medicine, 11, 491–493.

  5. Gregory, R.E., Ettinger, D.S. (1998). 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs, 2, 173–189.

  6. Zhang, X.J., Zhang, P. (2009). Advances in mechanism and treatment of chemotherapy-induced nausea and vomiting. Oncology Programme, 4(4), 348–354.

  7. Ma J, Han ZX. (2010). Hemotherapy-induced nausea and vomiting: research advances and management. Journal of Xuzhou Medical College. doi:10.3969/j.issn.1000-2065.2010.09.024.

  8. Navari, R. M., Gray, S. E., & Kerr, A. C. (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase Trial. Journal of Support Oncology, 9(5), 188–195.

    Article  CAS  Google Scholar 

  9. Passik, S. D., Kirsh, K. L., & Theobald, D. E. (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. Journal of Pain Symptom Management, 25(5), 485–488.

    Article  PubMed  Google Scholar 

  10. Bymaster F, Perry KW, Nelson DL (1999) Olanzapine: a basic science update. British Journal of Psychiatry Supplement, 37, 36–40.

  11. He, H., & Richardson, J. S. (1995). A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptor. International Clinical Psychopharmacology, 10(1), 19–30.

    Article  CAS  PubMed  Google Scholar 

  12. Schotte, A., Janssen, P. F., & Gommeren, W. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology, 124(1–2), 57–73.

    Article  CAS  PubMed  Google Scholar 

  13. Jordan, K., Kasper, C., & Schmoll, H. J. (2005). Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. European Journal of Cancer, 4(2), 199–205.

    Article  Google Scholar 

  14. Navari, R. M. (2006). Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews, 32(1), 50–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou, China

      Xin Wang, Lei Wang, Huayong Wang & Hao Zhang

    Authors
    1. Xin Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Lei Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Huayong Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Hao Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Lei Wang.

    Additional information

    Wang Lei and Wang Xin have contributed equally to the study and should be considered as co-first authors.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, X., Wang, L., Wang, H. et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys 72, 471–473 (2015). https://doi.org/10.1007/s12013-014-0489-0

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12013-014-0489-0

    Keywords

    Search

    Navigation